Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) - Rittmeyer, A; Gandara, D; Kowanetz, M; Mok, T; Fehrenbacher, L; Fabrizio, D; Otto, G; Malboeuf, C; Lieber, D; Paul, SM; Amler, L; Riehl, T; Schleifman, E; Cummings, C; Hegde, PS; Zou, W; Sandler, A; Ballinger, M; Shames, DS (Pneumologie, 2018)